EP Patent

EP3064224A1 — Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope

Assigned to Isotopia Molecular Imaging Ltd · Expires 2016-09-07 · 10y expired

What this patent protects

The present invention relates to a method for labeling a prostate-specific membrane antigen (PSMA) ligand with a radioactive isotope such as 68 Ga, 177 Lu, or 9 Y, and to a kit for carrying out this method. Radiolabeled PSMA ligands prepared by this method can be used for both…

USPTO Abstract

The present invention relates to a method for labeling a prostate-specific membrane antigen (PSMA) ligand with a radioactive isotope such as 68 Ga, 177 Lu, or 9 Y, and to a kit for carrying out this method. Radiolabeled PSMA ligands prepared by this method can be used for both imaging and therapy purposes.

Drugs covered by this patent

Patent Metadata

Patent number: EP3064224A1
Jurisdiction: EP
Classification: —
Expires: 2016-09-07
Drug substance claim: No
Drug product claim: No
Assignee: Isotopia Molecular Imaging Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.